

PTO/SB/68 (11-95)
Approved for use through 10/31/98. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

In re Application of	
<i>Backstrom et al</i>	
Application Number	Filed
08/736,267	Oct 24/96
Group Art Unit	Examiner

Paper No. #39

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE:

(A) referred to in United States Patent Number 5952008 column _____

(B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____ on page _____ of paper number _____

(C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____ or

(D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Anne Murphy
Signature
Anne MURPHY
Typed or printed name

6-27-01
Date

FOR PTO USE ONLY

Approved by: Gen
(initials)

Unit: F-714

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. ** The time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[54] PROCESSES FOR PREPARING COMPOSITIONS FOR INHALATION

4,690,952	9/1987	Kagatani et al.	514/11
4,746,508	5/1988	Carey et al.	424/88
4,788,221	11/1988	Kagatani et al.	514/12

[75] Inventors: Kjell Göran Erik Bäckström; Carl Magnus Olof Dahlbäck, both of Lund; Peter Edman, Bjärred; Ann Charlotte Birgit Johansson, Lund, all of Sweden

(List continued on next page.)

[73] Assignee: AB Astra, Södertälje, Sweden

FOREIGN PATENT DOCUMENTS

[*] Notice: This patent is subject to a terminal disclaimer.

43556/93	1/1994	Australia .
0 023 359	7/1980	European Pat. Off. .
0 055 041	12/1981	European Pat. Off. .
0 122 036	10/1984	European Pat. Off. .
0 200 383	4/1986	European Pat. Off. .
0 225 189	11/1986	European Pat. Off. .
0 272 097	6/1988	European Pat. Off. .
0 360 340	3/1990	European Pat. Off. .
0 455 463	11/1991	European Pat. Off. .

[21] Appl. No.: 08/858,122

(List continued on next page.)

[22] Filed: May 19, 1997

Related U.S. Application Data

[60] Continuation of application No. 08/468,418, Jun. 6, 1995, abandoned, which is a division of application No. 08/265, 237, Jun. 23, 1994, abandoned. *FWC*

[30] Foreign Application Priority Data

Jun. 24, 1993 [SE] Sweden	9302198
Feb. 4, 1994 [SE] Sweden	9400371

[51] Int. Cl.⁶ A61K 9/14; A61K 9/72; A61K 38/16; A61K 47/12

[52] U.S. Cl. 424/499; 424/46; 424/489; 424/502; 424/85.2; 424/434; 514/2; 514/3; 514/951; 530/399

[58] Field of Search 424/46, 489, 499, 424/502, 85.2, 434; 514/2, 3, 8, 12, 54, 58, 800, 802, 805-890, 350, 359, 951; 530/303, 306, 307, 308, 311, 313, 315, 398, 399; 930/50

[56] References Cited

U.S. PATENT DOCUMENTS

3,014,844	12/1961	Thiel .	
4,524,769	6/1985	Wetterlin	128/203.15
4,534,345	8/1985	Wetterlin	128/203.15
4,548,922	10/1985	Carey et al.	514/4
4,613,500	9/1986	Suzuki et al.	424/85.4
4,668,218	5/1987	Virtanen	604/58

Olanoff et al., "Method to Enhance Intranasal Peptide Delivery", in "Controlled-Release Technology Pharmaceutical Applications", Lee et al., Ed., Published 1987 by The American Chemical Society, pp. 301-309.

Mishima et al., "Studies on the Promoting Effects of Medium Chain Fatty Acid Salts on the Nasal Absorption of Insulin in Rats", J. Pharm. Sci., vol. 10, issued 1987, pp. 624-631.

(List continued on next page.)

Primary Examiner—Robert H. Harrison
Attorney, Agent, or Firm—Fish & Richardson P.C.

[57]

ABSTRACT

A pharmaceutical composition including a mixture of active compounds (A) a pharmaceutically active polypeptide, and (B) an enhancer compound which enhances the systemic absorption of the polypeptide in the lower respiratory tract of a patient, the mixture being in the form of a dry powder for inhalation in which at least 50% of the total mass of the active compounds consists of primary particles having a diameter less than or equal to about 10 microns, the primary particles optionally being formed into agglomerates.

49 Claims, 2 Drawing Sheets

